Construction Technology Innovation and Application Progress in the Disease of Humanized Zebrafish Model

doi:10.19586/j.2095-2341.2026.0019

Current Biotechnology ›› 2026, Vol. 16 ›› Issue (3): 618-625.DOI: 10.19586/j.2095-2341.2026.0019

• Reviews • Previous Articles Next Articles

Construction Technology Innovation and Application Progress in the Disease of Humanized Zebrafish Model

Xiaoyue SUN(), Ranran ZHU, Kechun LIU, Xuehui JIAN, Xue WANG, Yun ZHANG, Qing XIA, Yuanshuai YU, Hairong HOU, Chen SUN()

Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province，Biology Institute，Qilu University of Technology （Shandong Academy of Sciences），Jinan 250103，China

Received:2026-01-28 Accepted:2026-02-27 Online:2026-05-25 Published:2026-07-14
Contact: Chen SUN

Abstract

Abstract:

Humanized zebrafish models can accurately simulate human physiological and pathological processes， effectively overcome interspecies research barriers， and have become important research carriers in biomedicine. On this basis， the paper systematically elaborated on the inherent advantages of zebrafish for constructing humanized animal models， and comprehensively summarized the technical principles， characteristics and strengths of three commonly used approaches for establishing humanized zebrafish models， namely clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9（CRISPR/Cas9）， Tol2 transposon system， and xenotransplantation. It further highlighted the research progress and latest breakthroughs of humanized zebrafish models in multiple disease areas， including cardiovascular diseases， tumors， neurological disorders and liver diseases. Potential future research prospects were also proposed， including the combined application of diverse models and the integrated innovation of multiple technologies. The review aims to provide technical references for researchs in humanized zebrafish models and further advance studies on pharmaceutial research and development.

Key words: humanized zebrafish models, gene editing, transposon, xenotransplantation

CLC Number:

Q95.33

Xiaoyue SUN, Ranran ZHU, Kechun LIU, Xuehui JIAN, Xue WANG, Yun ZHANG, Qing XIA, Yuanshuai YU, Hairong HOU, Chen SUN. Construction Technology Innovation and Application Progress in the Disease of Humanized Zebrafish Model[J]. Current Biotechnology, 2026, 16(3): 618-625.

Add to citation manager EndNote|Ris|BibTeX

URL: https://swjsjz.magtechjournal.com/EN/10.19586/j.2095-2341.2026.0019

https://swjsjz.magtechjournal.com/EN/Y2026/V16/I3/618

Figures/Tables 3

References 49

[1]	魏泓.医学动物实验技术[M].北京:人民卫生出版社, 2016.
[2]	HAMMER H S. Water quality for zebrafish culture[M]. The Zebrafish in Biomedical Research. Academic Press, 2020.
[3]	JOÃO B, TEIXEIRA D, MICHAEL A, et al.. Toxicology of Essential and Xenobiotic Metals[M]. Boca Raton: CRC Press, 2024.
[4]	COPPOLA A, LOMBARI P, MAZZELLA E, et al.. Zebrafish as a model of cardiac pathology and toxicity: spotlight on uremic toxins[J/OL]. Int. J. Mol. Sci., 2023, 24(6): 5656[2026-03-11]. .
[5]	COOPER G, NORTH R, HUNT-SMITH T, et al.. Persistent metabolic changes are induced by 24 h low-dose lead (Pb) exposure in zebrafish embryos[J/OL]. Int. J. Mol. Sci., 2025, 26(3): 1050[2026-03-11]. .
[6]	MEUSER A V, PITURA A R, MANDEVILLE E G. A high-quality reference genome for the common creek chub, Semotilus atromaculatus [J/OL]. G3, 2024, 14(2): jkad283[2026-03-11]. .
[7]	DENG Y, QIAN Y, MENG M, et al.. Extensive sequence divergence between the reference genomes of two zebrafish strains, Tuebingen and AB[J]. Mol. Ecol. Resour., 2022, 22(6): 2148-2157.
[8]	李玉姣,郭健敏,黄远铿,等.斑马鱼在药理毒理研究中的应用进展[J].中南药学,2024,22(10):2725-2728.
	LI Y J, GUO J M, HUANG Y K, et al.. Progress in the application of zebrafish in pharmacological and toxicological research[J]. Cent. South Pharm., 2024, 22(10): 2725-2728.
[9]	SASSEN W A, KÖSTER R W. A molecular toolbox for genetic manipulation of zebrafish[J]. Adv. Genom. Genet., 2015, 5: 151-163.
[10]	HUANG M, JIA Z, LIU Y, et al.. A zebrafish immunodeficiency model induced by the combination of Tacrolimus and Everolimus for rapid assessment of immune-enhancing agents[J/OL]. BioRxiv, 2025, 4: 647472[2026-01-12]. .
[11]	FEHRENBACH A, MITROFANOV A, ALKHNBASHI O S, et al.. SpacerPlacer: ancestral reconstruction of CRISPR arrays reveals the evolutionary dynamics of spacer deletions[J]. Nucleic Acids Res., 2024, 52(18): 10862-10878.
[12]	SHAMSUDHEEN M S. Beyond the scissors: CRISPR-Cas9's precision in CAR-T cell therapy[J/OL]. J. Biol. Life Sci., 2025, 16(2): 57[2026-03-11]. .
[13]	张俊有,王棨临,刘倩,等.CRISPR/Cas基因编辑技术在增强子功能分析及鉴定中的研究进展[J].中国生物工程杂志,2022,42(4):24-32.
	ZHANG J Y, WANG Q L, LIU Q, et al.. Research progress of CRISPR/Cas gene editing technology in enhancer function analysis and identification[J]. China Biotechnol., 2022, 42(4): 24-32.
[14]	ALVARES K V, SILVA J F, DE OLIVEIRA C L B. Shaping agricultural future: a comprehensive review on crispr technology applications in agriculture[J/OL]. Rev. Bras. De Engenharia De Biossistemas, 2024, 18: 1227[2026-03-11]. .
[15]	贾名扬,王磊,陈俊峰,等.CRISPR/Cas9基因编辑技术在畜禽育种中的研究进展[J].生物技术进展,2024,14(4):529-536.
	JIA M Y, WANG L, CHEN J F, et al.. Research progress of CRISPR/Cas9 gene editing technology in livestock and poultry breeding[J]. Curr. Biotechnol., 2024, 14(4): 529-536.
[16]	李仪扬,周执政,王淑菲,等.CRISPR/Cas9基因编辑技术在疾病治疗中的应用与展望[J].生物技术进展,2025,15(1):35-42.
	LI Y Y, ZHOU Z Z, WANG S F, et al.. Application and prospect of CRISPR/Cas9 gene editing technology in disease treatment[J]. Curr. Biotechnol., 2025, 15(1): 35-42.
[17]	KOGA A, SUZUKI M, INAGAKI H, et al.. Transposable element in fish[J/OL]. Nature, 1996, 383(6595): 30[2026-03-11]. .
[18]	SANDOVAL-VILLEGAS N, NURIEVA W, AMBERGER M, et al.. Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering[J/OL]. Int. J. Mol. Sci., 2021, 22(10): 5084[2026-03-11]. .
[19]	WANG P C, DENG H, XU R, et al.. Improvement in Tol2 transposon for efficient large-cargo capacity transgene applications in cultured cells and zebrafish (Danio rerio)[J]. Zool. Res., 2024, 45(3): 567-574.
[20]	DING Y, VAN DER KOLK K J, VAN DER ENT W, et al.. Automated microinjection for zebrafish xenograft models[J/OL]. NPJ Biomed. Innov., 2025, 2: 13[2026-03-11]. .
[21]	SOMASAGARA R R, HUANG X, XU C, et al.. Targeted therapy of human leukemia xenografts in immunodeficient zebrafish[J/OL]. Sci. Rep., 2021, 11: 5715[2026-03-11]. .
[22]	黄晞傲.斑马鱼异种移植肿瘤模型在抗肿瘤药物开发具有广阔前景[J/OL].医学与公共健康,2025, 1(6): 2[2026-01-12].
	HUANG X. Zebrafish xenograft tumor models hold broad prospects in antitumor drug development[J/OL]. Med. Public Health, 2025, 1(6): 2[2026-01-12]. .
[23]	MYERS T D. Investigation of pathological processes in a novel murine model of triosephosphate isomerase deficiency and assessment of potential therapeutics[D]. University of Pittsburgh, 2024.
[24]	SUN P, LI Y, LIU F, et al.. Generation and analysis of TPI deficiency zebrafish model[J]. Hereditas, 2024, 46(3): 232-241.
[25]	NIE X, LU Z. Metabolic modulation in dilated cardiomyopathy: from pathophysiology to therapy[J/OL]. Rev. Cardiovasc. Med., 2025, 26(11): 45518[2026-03-11]. .
[26]	LAMPUGNANI M G, DEJANA E, GIAMPIETRO C. Vascular endothelial (VE)-cadherin, endothelial adherens junctions, and vascular disease[J/OL]. Cold Spring Harb. Perspect. Biol., 2018, 10(10): a029322[2026-03-11]. .
[27]	LU S, HU M, WANG Z, et al.. Generation and application of the zebrafish heg1 mutant as a cardiovascular disease model[J/OL]. Biomolecules, 2020, 10(11): 1542[2026-03-11]. .
[28]	GROSS A, ZHOU B, BEWERSDORF L, et al.. Desmoplakin maintains transcellular keratin scaffolding and protects from intestinal injury[J]. Cell. Mol. Gastroenterol. Hepatol., 2022, 13(4): 1181-1200.
[29]	WANG W, MURRAY B, TICHNELL C, et al.. Clinical characteristics and risk stratification of desmoplakin cardiomyopathy[J]. Europace, 2022, 24(2): 268-277.
[30]	CELEGHIN R, RISATO G, BEFFAGNA G, et al.. A novel DSP zebrafish model reveals training- and drug-induced modulation of arrhythmogenic cardiomyopathy phenotypes[J/OL]. Cell Death Discov., 2023, 9: 441[2026-03-11]. .
[31]	MERCATALI L, LA MANNA F, GROENEWOUD A, et al.. Development of a patient-derived xenograft (PDX) of breast cancer bone metastasis in a zebrafish model[J/OL]. Int. J. Mol. Sci., 2016, 17(8): 1375[2026-03-11]. .
[32]	YIN J, ZHAO G, KALIRAI H, et al.. Zebrafish patient-derived xenograft model as a preclinical platform for uveal melanoma drug discovery[J/OL]. Pharmaceuticals, 2023, 16(4): 598[2026-03-11]. .
[33]	YENİ Y, NİNİNG N. Homology modeling epitopes of Kirsten rat sarcoma (KRAS) G12D, G12V and G12R as pancreatic ductal adenocarcinoma vaccine candidates[J]. Turk. Comput. Theor. Chem., 2023, 7(1): 62-71.
[34]	BUDAGYAN K, CANNON A C, CHATOFF A, et al.. KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation[J/OL]. Cell Rep., 2025, 44(4): 115444[2026-03-11]. .
[35]	NGUYEN A T, EMELYANOV A, KOH C H V, et al.. A high level of liver-specific expression of oncogenic KrasV12 drives robust liver tumorigenesis in transgenic zebrafish[J]. Dis. Models Mech., 2011, 4(6): 801-813.
[36]	AI X, YE Z, XIAO C, et al.. Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish[J/OL]. Dis. Models Mech., 2022, 15(4): dmm049109[2026-03-11]. .
[37]	JIN Y, WEI L, JIANG Q, et al.. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model[J/OL]. Sci. Rep., 2018, 8: 15837[2026-03-11]. .
[38]	MAMMANA A. Skin as a promising biomatrix for the early detection of misfolded proteins by RT-QuIC[D]. Alma Mater Studiorum Università di Bologna, 2023.
[39]	王晶莹,任彬彬,马素娜,等.α-突触核蛋白在帕金森疾病中诱导线粒体损伤的机制[J].中国组织工程研究,2025,29(17):3668-3674.
	WANG J Y, REN B B, MA S N, et al.. Mechanism of alpha-synuclein in mitochondrial damage induced by Parkinson's disease[J]. Chin. J. Tissue Eng. Res., 2025, 29(17): 3668-3674.
[40]	ZINI S, MUSCÒ A, LONGHENA F, et al.. A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage[J/OL]. Neurobiol. Dis., 2025, 213: 107018[2026-03-11]. .
[41]	FERREIRA J. A new zebrafish epilepsy model[J/OL]. Lab Anim., 2025, 54(8): 196[2026-03-11]. .
[42]	BREIJYEH Z, KARAMAN R. Comprehensive review on Alzheimer's disease: causes and treatment[J/OL]. Molecules, 2020, 25(24): 5789[2026-03-11]. .
[43]	PU Y Z, LIANG L, FU A L, et al.. Generation of Alzheimer's disease transgenic zebrafish expressing human APP mutation under control of zebrafish appb promotor[J]. Curr. Alzheimer Res., 2017, 14(6): 668-679.
[44]	MEGHADRI S H, MARTINEZ-DELGADO B, OSTERMANN L, et al.. Loss of serpina1 in mice leads to altered gene expression in inflammatory and metabolic pathways[J/OL]. Int. J. Mol. Sci., 2022, 23(18): 10425[2026-03-11]. .
[45]	DE GRACIA L, NORIEGA L, SÁNCHEZ E, et al.. Protease S and Z inhibitor genotypes in the SERPINA1 gene in patients with COPD in the republic of Panama [J/OL]. Genet. Clin. Genom., 2025: 3(1): 11-17.
[46]	YIP E, GIOUSOH A, FUNG C, et al.. A transgenic zebrafish model of hepatocyte function in human Z α1-antitrypsin deficiency[J]. Biol. Chem., 2019, 400(12): 1603-1616.
[47]	ZHANG Q, LI F, GE Q, et al.. YBX1/CD36 positive feedback loop-mediated lipid accumulation drives metabolic dysfunction-associated steatotic liver disease[J]. Int. J. Biol. Sci., 2025, 21(5): 2118-2134.
[48]	WU S Y, YANG W Y, CHENG C C, et al.. Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling[J/OL]. Clin. Transl. Med., 2020, 10(8): e252[2026-03-11]. .
[49]	POON K L, WANG X, NG A S, et al.. Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates[J]. Arch. Toxicol., 2017, 91(3): 1187-1197.

Construction Technology Innovation and Application Progress in the Disease of Humanized Zebrafish Model

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 49

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yiyang LI, Zhizheng ZHOU, Shufei WANG, Boya LIU, Yufei LIU, Xiaoyan LI, Hongshu SUI, Dongwei LIU. Application and Prospect of CRISPR/Cas9 Gene Editing Technology in Disease Treatment [J]. Current Biotechnology, 2025, 15(1): 35-42.
[2]	Guang HU, Zhi WANG, Wei FU, Yuting SHI, Shanshan CHEN, Liang LUO, Shuang WEI. Establishment of Detection Method Based on TaqMan Real-time Fluorescence Quantitative PCR Technology for OsWx-edited Rice [J]. Current Biotechnology, 2025, 15(1): 86-92.
[3]	Jing WANG, Haitao GUAN, Xiaolei ZHANG, Baohuai WANG, Baohai LIU, Hongtao WEN. Detection Dynamic and Development Tendency of Agricultural Gene Editing Products [J]. Current Biotechnology, 2024, 14(5): 712-723.
[4]	Mingyang JIA, Lei WANG, Junfeng CHEN, Jiaqing ZHANG, Xiangzhou YAN, Baosong XING, Jing WANG. Research Progress of CRISPR/Cas9 Gene Editing Technology in Livestock and Poultry Breeding [J]. Current Biotechnology, 2024, 14(4): 529-536.
[5]	Jingsheng TAN, Guantao ZHAO, Li ZHU, Yubin LI. The Sequence Characterization of Somatic Excision Footprints from Two-element Transposable System of rMrh/Mrh in Maize [J]. Current Biotechnology, 2024, 14(4): 601-609.
[6]	Kehao CAO, Junli ZHU, Huashan HE, Weizhuo XU. Impact of the Fourth Modifications of Patent Laws on Biotechnology Patent Applications and Industry Development [J]. Current Biotechnology, 2023, 13(5): 663-670.
[7]	Ali WANG, Jiangdong LIU. Research Progress on the CRISPR/Cas System in Zebrafish [J]. Current Biotechnology, 2023, 13(4): 485-491.
[8]	Siyu GAI, Ziqi CHEN, Hanchao XIA, Rengui ZHAO, Xiangguo LIU. Research Progress of CRISPR/Cas9 Technology in Plant Promoter Editing [J]. Current Biotechnology, 2023, 13(3): 321-328.
[9]	Hui SUN, Chunyi ZHANG, Ling JIANG. Progress of Plant Molecular Farming in Pharmaceutical Use [J]. Current Biotechnology, 2023, 13(1): 65-71.
[10]	Yang YANG, Fenglin WANG, De LIU, Yuanyuan LUO, Jianhua ZHU. Research Progress of CRISPR‍⁃‍Cas9 Technology on the Production of Plant Secondary Metabolites [J]. Current Biotechnology, 2022, 12(6): 806-816.
[11]	Kun YU, Jiaqi XUE, Jinkuan WANG, Yongtao YU. Research Progress on Application of CRISPR/Cas9 Gene Editing Technique in Filamentous Fungi [J]. Current Biotechnology, 2022, 12(5): 696-704.
[12]	Xing DANG, Binwei ZHI, Kehao CAO, Tingting LIU, Biao CHEN, Yuanjie DING. Patent Analysis on Genetically Modified Maize Biological Breeding Technology and Development Suggestions [J]. Current Biotechnology, 2022, 12(4): 614-622.
[13]	Weisong GAO, Jinping DOU, Shuang WEI, Xingjian LIU, Zhifang ZHANG, Yinyu LI. Classification and Research Status of CRISPR/Cas Systems [J]. Current Biotechnology, 2022, 12(4): 532-538.
[14]	Yaohui HUANG, Yijie WANG, Litao YANG, Yue JIAO, Zhongwen FU. Safety Management of the Crop Produced by New Breeding Techniques [J]. Current Biotechnology, 2022, 12(2): 198-204.
[15]	Mengyu WANG, Haoqian WANG, Xujing WANG, Zhixing WANG. Research Progress of Gene Editing Products Detection Technology [J]. Current Biotechnology, 2021, 11(4): 438-445.